Stefan Gluck, VP, Celgene to Speak at GTCbio’s 2nd Cancer Diagnostics Conference (Nov. 2016)

Monrovia, CA, September 09, 2016 --(PR.com)-- Stefan Glück, MD, PhD, is the Vice President of Global Medical Affairs at Celgene Corporation since October 2014. He is a medical oncologist with a focus on breast cancer.

As VP of Global Medical Affairs, he oversees breast, ovarian and bladder cancer activities worldwide for the Celgene Corporation as well as the Immuno-Oncology Program. More recently, he also leads the GI section including pancreas cancer. His interest has been in clinical trials in breast cancer and he has been a PI of 37 clinical studies in breast cancer in Miami, and investigator in numerous scientific, translational projects.

Network with colleagues to discuss new research in cancer diagnostics, including next generation sequencing, the use of clinical utility of cell-free DNA liquid biopsy, patient selection for cancer drug development, and correlative predictive markers.

This conference is also part of the larger Novel Cancer Therapeutics Summit, which consists of three additional conferences including this meeting:

Cancer Immunotherapy
2nd Cancer Diagnostics
5th Cancer Epigenetics
5th Oncology Partnering & Deal Making

For more information, please visit website: https://www.gtcbio.com/conferences/cancer-diagnostics-agenda

GTCbio
635 W. Foothill Blvd
Monrovia, CA 91016
www.gtcbio.com/
Email: infogtcbio@gtcbio.com
Phone: (626) 256-6405
Fax: (626) 466-4433